HCAT Form 144 Filed for 2,613 Restricted Shares Sale on 09/02/2025
Rhea-AI Filing Summary
Health Catalyst, Inc. (HCAT) filing of Form 144 notifies the market that 2,613 shares of common stock will be offered for sale through Morgan Stanley Smith Barney on 09/02/2025. The filing lists an aggregate market value of $8,786.74 for the shares based on the transaction and shows 70,373,625 shares outstanding for the issuer.
The shares were acquired the same day, 09/02/2025, as restricted stock from Health Catalyst and are identified as compensation. The filer discloses a prior restricted-stock sale of 2,712 shares on 06/02/2025 yielding gross proceeds of $9,857.58. By signing, the person attests they are unaware of undisclosed material adverse information about the issuer.
Positive
- Complete Rule 144 disclosure including broker, share count, market value, acquisition details, and prior sales
- Attestation present that the filer does not possess undisclosed material adverse information
- Transaction tied to compensation, and acquisition date is explicitly stated as 09/02/2025
Negative
- None.
Insights
TL;DR: This Form 144 is a routine insider sale notice disclosing a small compensation-related sale of 2,613 shares.
The filing contains standard Rule 144 disclosure: broker details (Morgan Stanley Smith Barney), number of shares (2,613), aggregate market value ($8,786.74), and outstanding share count (70,373,625). The securities were acquired as restricted stock on the sale date and were paid as compensation, which indicates these are proceeds from an insider compensation event rather than a market purchase. The filing also lists a recent prior restricted-stock sale of 2,712 shares on 06/02/2025 for $9,857.58, which provides context on recent insider liquidity. No earnings, material contracts, or regulatory issues are disclosed here.
TL;DR: Disclosure appears complete for a Rule 144 notice; signature attestation confirms no undisclosed material information.
The document includes required information: relationship to issuer (implicit through compensation), acquisition date and nature (restricted stock), nature of payment (compensation), broker, and planned sale date. The signer affirms absence of material nonpublic information in the issuer, a standard legal attestation. The filing does not include any governance changes, insider departures, or other corporate actions.